Cobicistat: Additional Phase II data

Additional data from the double-blind Phase II GS-US-216-0105 trial in 79 treatment-naïve patients with HIV RNA level >=5,000 copies/mL showed that the proportion of patients who achieved HIV RNA levels <50 copies/mL at 48 weeks was 82% for cobicistat-boosted Reyataz atazanavir plus Truvada emtricitabine/tenofovir vs. 86% for Norvir ritonavir-boosted Reyataz plus Truvada. Data were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston. ...